Terumo India introduces ReDS™ Pro to detect pulmonary congestion in heart failure patients
New Delhi: Terumo India, the Indian arm of Japanese firm Terumo Corporation, has introduced ReDS Pro, an innovative non-invasive technology to detect pulmonary congestion in heart failure patients in India.
Heart Failure (HF) is becoming a major burden in India and is associated with high morbidity and mortality. Congestive heart failure affects about 10 million people in India (1). Most of the time, the earliest manifestation is attributed to congestion during the course of disease. Acute heart failure (AHF) decompensation leads to pulmonary congestion which is considered to be the main cause of hospitalization and rehospitalization (2). The rehospitalization rate for heart failure patients with reduced ejection fraction is 37%, indicating a high burden of congestive heart failure (CHF) related hospitalisations in the Indian population (3). Till date, there has been no definitive non-invasive tool for assessment of the same. ReDS™ Pro is US Food and Drug Administration (USFDA) and Conformité Européenne (CE) approved device that measures pulmonary congestion to help early detection of worsening disease. It has a good sensitivity and specificity which has been studied against CT scan. Trials have shown a reduction in hospitalisation rates amongst heart failure patients managed using ReDS™ Pro.
“Each episode of hospitalization imposes significant distress and financial burden on the patient as well as the healthcare system of the country. Therefore, early detection of pulmonary congestion is crucial for altering the course of the disease and ensuring prompt therapeutic intervention. Understanding this critical need, we are delighted to introduce ReDS™ for India as it will enable doctors and healthcare professionals to promptly and accurately assess pulmonary congestion levels in a patient within 45 seconds, ensuring an opportunity for early therapeutic intervention and reducing hospitalization rates, said Dr. Daniel R Bensimhon, Medical Director, Cone Health Group, USA.
The Remote Dielectric Sensing (ReDS™ Pro) device works by non-invasively measuring the total fluid volume in the lungs and the result is displayed as percentage (%) of the total volume of the lungs within 45 seconds. The device consists of a bedside console connected to a sensor unit which can be placed over light clothing. Since the device is safe to use, it allows periodic monitoring of the treatment of heart failure patients.
It is approved to be used for patients with fluid management problems, taking diuretic medication, living with heart failure, and recovering from coronary artery disease or a related event. It finds its utility in outpatient clinics, emergency departments, and heart failure wards to identify pulmonary congestion in these patients.
Terumo India is the part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. It is a fast-growing medical devices company that provides high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India.
References
1. Chaturvedi V, Parakh N, Seth S, Bhargava B, Ramakrishnan S, Roy A, Saxena A, Gupta N, Misra P, Rai SK, Anand K, Pandav CS, Sharma R, Prasad S. Heart failure in India: The INDUS (INDia Ukieri Study) study. J Pract Cardiovasc Sci 2016;2:28-35
2. Pirrotta F, Mazza B, Gennari L, Palazzuoli A. Pulmonary Congestion Assessment in Heart Failure: Traditional and New Tools. Diagnostics. 2021; 11(8):1306. https://doi.org/10.3390/diagnostics11081306
3. Bhosale KH, et al. Rate of Rehospitalization in 60 Days of Discharge and It's Determinants in Patients with Heart Failure with Reduced Ejection Fraction in a Tertiary Care Centre in India. Int J Heart Fail. 2020;2(2):131-144. Published 2020 Apr 21. doi:10.36628/ijhf.2020.0007]
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Terumo.
